pentobarbital will lessen the level or effect of roflumilast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not recommended; solid cytochrome P450 enzyme inducers lower systemic publicity to roflumilast and could reduce the therapeutic successpentobarbital will minimize the extent or result of doravirine